Ovarian cancer stem cell-specific gene expression profiling and targeted drug prescreening

Yuting Huang1, Baohui Ju1, Jing Tian1

  • 1Department of Gynecological Oncology, Tianjin Medical Univerisity Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, P.R. China.

Oncology Reports
|January 16, 2014
PubMed

Insights

Researchers identified key molecular signatures in ovarian cancer stem cells (OVCSCs) to find new drugs. Several small molecules show potential for targeting and eliminating these resistant OVCSCs, offering hope for new ovarian cancer treatments.

Area of Science:

  • Genomics and Molecular Biology
  • Oncology
  • Stem Cell Biology

Background:

  • Ovarian cancer stem cells (OVCSCs) possess self-renewal and drive tumor initiation, relapse, and drug resistance.
  • Effective strategies to eliminate OVCSCs are currently lacking.
  • Understanding OVCSC molecular profiles is crucial for developing targeted therapies.

Purpose of the Study:

  • To compare gene expression profiles of OVCSCs with normal ovarian cells and non-stem ovarian cancer cells.
  • To identify molecular signatures and pathways involved in ovarian cancer progression and stemness.
  • To prescreen small-molecule compounds with potential anti-OVCSC activity.

Main Methods:

  • Genome-wide expression profiling of different ovarian cancer stemness groups (SDC, SP1, SP2) versus non-stemness controls.
  • Differential gene expression analysis (fold-change >1.5, P<0.05).
  • Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis.
  • Gene co-expression extrapolation screening using the Connectivity Map.

Main Results:

  • Identified 6495, 1347, and 509 differentially expressed genes in SDC, SP1, and SP2 groups, respectively.
  • Commonly upregulated genes: NAB1, NPIPL1. Commonly downregulated genes: PROS1, GREB1, KLF9, MTUS1.
  • Enriched KEGG pathways include ECM receptor, ErbB signaling, endocytosis, and adherens junction.
  • Predicted small molecules like SC-560, disulfiram, thapsigargin, esculetin, and cinchonine show potential anti-OVCSC properties.

Conclusions:

  • Key molecular signatures and regulatory networks in OVCSCs have been identified.
  • Several small molecules demonstrate potential for targeting OVCSC-specific genes.
  • These findings may facilitate the development of novel OVCSC-targeted drugs for ovarian cancer.